Jan 22, 2016 @ 3:00pm $6.56
At least it appears to. The evidence that their system for attacking liver cancer is very compelling. See their site http://delcath.com/chemotherapy/
Delcath will soon prove, or fail to prove, to the FDA that their technology for treating liver cancer is safe and effective. If they are successful, I expect Delcath will have very substantial growth in their revenues, earnings and their stock price. I am very optimistic. The risks are high, if they fail, so will their stock’s price.